Millipore Sigma Vibrant Logo

70839 Origami™ B(DE3)pLysS Competent Cells - Novagen

View This Product on Sigma-Aldrich
70839
価格&在庫状況を照会

概要

Replacement Information

価格&在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
70839-3CN
在庫状況検索中…
現在国内在庫なし
現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      樹脂アンプル 0.4 ml
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示 
      値引
      ()
       
      弊社照会
      70839-4CN
      在庫状況検索中…
      現在国内在庫なし
現在国内在庫なし
      現在国内在庫有り 
      販売中止
      在庫僅少
      現在国内在庫あり
        Remaining : Will advise
          Remaining : Will advise
          注文対象外
          お問合せください
          Contact Customer Service

          ガラスビン 1 ml
          価格を検索中…
          価格が見つかりません
          Minimum Quantity needs to be mulitiple of
          Maximum Quantity is
          弊社照会 詳細を表示 
          値引
          ()
           
          弊社照会
          Description
          OverviewOrigami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.

          DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

          pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability.
          Genotype: F- ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)


          This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




          This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
          Catalogue Number70839
          Brand Family Novagen®
          References
          Product Information
          Components
          Guaranteed efficiencyGuaranteed efficiency: > 2 x 10⁶ cfu/μg
          Quality LevelMQ100
          Applications
          Biological Information
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Multiple Toxicity Values, refer to MSDS
          Storage ≤ -70°C
          Do not freeze Ok to freeze
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications
          Global Trade Item Number
          カタログ番号 GTIN
          70839-3CN 07790788052836
          70839-4CN 07790788052843

          Documentation

          Origami™ B(DE3)pLysS Competent Cells - Novagen 試験成績書(CoA)

          タイトルロット番号
          70839

          カタログ

          タイトル
          Competent Cell Brochure

          引用

          Title
        • Megan M. Kibbey, et al. (2006) Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to IGF-1 binding. Molecular Pharmacology 69, 833-845.
        • James Flint, et al. (2005) Probing the mechanism of ligand recognition in family 29 carbohydrate-binding molecules. Journal of Biological Chemistry 280, 23718-23726.
        • ユーザープロトコール

          タイトル
          TB009 Competent Cells
          TB053 Academic and Non-profit Laboratory Assurance Letter

          関連製品&アプリケーション

          Related Products

          カタログ番号 説明  
          70836 Origami™ B Competent Cells - Novagen 価格&在庫状況を表示
          70837 Origami™ B(DE3) Competent Cells - Novagen 価格&在庫状況を表示
          70911 Origami™ B Competent Cell Set - Novagen 価格&在庫状況を表示

          関連製品: Brand Facete

          カテゴリー

          Life Science Research > Genomic Analysis > Transfection and Protein Expression > Bacterial Expression > Competent Cells for Expression